ELANQT52Elanco Animal Health Incorporated·NYSE
23.06-0.77%
News
Down 0.8% — 4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.40Insider Own1.14%Shs Outstand499.45MPerf Week2.40%
Market Cap11.52BForward P/E18.23EPS next Y1.27Insider Trans1.21%Shs Float494.51MPerf Month5.93%
Enterprise Value14.91BPEG—EPS next Q0.21Short Float6.29%Perf Quarter-10.34%
Income-199.00MP/S2.29EPS this Y21.36%Short Ratio4.97Perf Half Y2.44%
Sales5.02BP/B1.75EPS next Y11.74%ROA-1.47%Short Interest31.11MPerf YTD1.90%
Book/sh13.19P/C21.73EPS next 5Y10.15%ROE-3.02%52W High27.98 -17.58%Perf Year2.08%
Cash/sh1.06P/FCF30.39EPS past 3/5Y—ROIC3.92%52W Low19.40 18.87%Perf 3Y160.27%
Dividend Est.—EV/EBITDA19.26Sales past 3/5Y2.25% 7.57%Gross Margin52.59%Volatility2.54% 2.91%Perf 5Y-31.98%
Dividend TTM—EV/Sales2.97EPS Y/Y TTM-146.19%Oper. Margin9.20%ATR (14)0.68Perf 10Y—
Dividend Ex-Date—Quick Ratio1.09Sales Y/Y TTM11.95%Profit Margin-3.96%RSI (14)52.46Recom2.41
Dividend Gr. 3/5Y—Current Ratio2.05EPS Q/Q30.77%SMA201.16%Beta1.73Target Price26.67
Payout0.00%Debt/Eq0.59Sales Q/Q10.23%SMA50-0.28%Rel Volume0.56Prev Close23.24
Employees9,650LT Debt/Eq0.58EarningsNov 06SMA200-3.08%Avg Volume6.16MPrice23.06
IPO DateSep 20, 2018Option/ShortYes / YesEPS/Sales Surpr.26.30% 4.23%Net Debt/EBITDA4.38Volume3,453,605Change-0.77%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-20-26DowngradeJefferiesBuy → Hold$24
Aug-06-26ReiteratedKeybancOverweight$29 → $30
Jul-22-26ReiteratedMorgan StanleyEqual Weight$23 → $26
May-15-26ReiteratedMorgan StanleyEqual Weight$24 → $23
Feb-25-26ReiteratedKeybancOverweight$27 → $29
Feb-24-26ReiteratedLeerink PartnersOutperform$18 → $30
Jan-29-26ReiteratedUBSBuy$27 → $30
Jan-22-26UpgradePiper SandlerNeutral → Overweight$12 → $30
Dec-18-25ReiteratedMorgan StanleyEqual Weight$37 → $22
Dec-08-25InitiatedBarclaysOverweight$22 → $30
Latest News· Times ET
Oct-30-26
Oct-22-26
Oct-20-26
Oct-19-26
Oct-16-26
Oct-09-26
Oct-06-26
Sep-26-26
Sep-24-26
Sep-22-26
Sep-19-26
Sep-18-26
Company

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5,0204,7154,4394,417—————
Cost of Goods Sold Incl. D&A2,3802,6652,5302,479—————
Gross Profit2,6402,0501,9091,938—————
Selling, General and Administrative Excl. Other1,5191,4301,3141,285—————
Research and Development371368344327—————
Other Operating Expense
288000—————
Operating Income462252251326—————
Interest Expense259220339277—————
Unusual Expense
—————————
Non-Operating Income (Expense)-369-256576-1,244—————
Net Income Before Taxes-166-224488-1,195—————
Income Taxes33815036—————
Consolidated Net Income-199-232338-1,231—————
Net Income From Continuing Operations-199-232338-1,231—————
Net Income-199-232338-1,231—————
EPS (Recurring)-0.41-0.470.68-2.50—————
EPS (Basic, Before Extraordinaries)-0.41-0.470.68-2.50—————
EPS (Diluted)-0.40-0.470.68-2.50—————
EBITDA7746761,489-224—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——17.81——————
Price To Sales Ratio2.302.381.351.66—————
Gross Margin52.5943.4843.0143.88—————
Operating Margin9.205.345.657.38—————
Net Margin-3.96-4.927.61-27.87—————
Shares Outstanding500496494492—————
Market Capitalization11,53011,2245,9827,331—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.26$25.18$22.09$19.01$15.93● Close Price0.00M0.37M0.74M1.10M1.47MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bettington Timothy JOfficerOct 15 '26Sale23.004,350100,050138,911Oct 19
Kurzius Lawrence ErikDirectorAug 20 '26Buy23.4040,000935,920188,647Aug 21
O'Neill ShivGC AND CORP SECAug 18 '26Buy23.583,99894,27387,832Aug 18
Harrington Michael JDirectorAug 12 '26Buy21.825,000109,100131,451Aug 13
VanHimbergen Robert MEVP and CFOAug 07 '26Buy23.084,20096,926137,516Aug 10
Herendeen PaulDirectorAug 07 '26Buy23.6810,000236,850111,687Aug 10
Modi Rajeev A.OfficerMay 15 '26Buy20.354,91199,939160,812May 19
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16
Modi Rajeev A.OfficerDec 11 '25Buy21.334,50095,985123,082Dec 15
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11
Kurzius Lawrence ErikDirectorMar 07 '25Buy10.9010,000109,000101,459Mar 11
HOOVER R DAVIDDirectorMar 05 '25Buy10.9025,000272,558210,000Mar 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.